- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| Mi | Adial Pharmaceuticals, Inc: Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 | 108 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| Di | Adial Pharmaceuticals announces 1-for-25 reverse stock split | 2 | Investing.com | ||
| Di | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement | 67 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 14.01. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 | 2 | GlobeNewswire (USA) | ||
| 06.01. | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| ADIAL PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.11.25 | Adial Pharmaceuticals raises $2.86 million through warrant exercise | 1 | Investing.com | ||
| 26.11.25 | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds | 1 | GlobeNewswire (USA) | ||
| 14.11.25 | Adial Pharmaceuticals GAAP EPS of -$0.08 | 6 | Seeking Alpha | ||
| 14.11.25 | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | 331 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 14.11.25 | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | ADIAL PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 17.10.25 | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show | 1 | GlobeNewswire (USA) | ||
| 09.10.25 | Adial completes key validation for alcohol disorder treatment test | 1 | Investing.com | ||
| 09.10.25 | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution | 151 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 16.09.25 | Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder | 2 | Benzinga.com | ||
| 16.09.25 | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09.25 | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 | 284 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 09.09.25 | ADIAL PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,148 | +0,79 % | SDAX: Evotec-Aktie schießt zweistellig nach oben | Eine Kaufempfehlung von Berenberg entfacht neuen Optimismus bei Evotec und katapultiert die Biotech-Aktie an die Indexspitze. Die Aktie der Evotec hat am Dienstagmittag ein Kursfeuerwerk gezündet und... ► Artikel lesen | |
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 43,170 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| PAION | 0,200 | +8,11 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WIRD GEPRUEFT | Fuer folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wird ein Mistrade-Antrag geprueft:ISIN Datum Zeit Volumen Preis Fair Value (AS)DE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| STRYKER | 302,10 | -0,33 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders... ► Artikel lesen | |
| BIOFRONTERA | 2,420 | -1,22 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,910 | 0,00 % | HEIDELBERG PHARMA AG zeigt klare Stärke im Trend | ||
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| CO.DON | 0,017 | -21,43 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BIOXXMED | 1,328 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| OCUGEN | 1,150 | +1,05 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen |
Das Unternehmen ADIAL PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADIAL PHARMACEUTICALS INC finden Sie auf Wallstreet Online.